Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
In All, PortfolioCRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that, following discussions with the FDA, it has finalized…